Health-care analyst Lauren Migliore looks at what makes a biotech firm a likely takeout candidate and reveals our top five biotech M&A picks for 2010.
Morningstar's Gaston Ceron addresses the short- and long-term prospects for and opportunities in ICE's takeover of NYSE Euronext.
2011 was a relatively light year for biotech M&A, but it looks like activity is picking up in 2012.
High levels of merger and acquisition activity will be the big theme of year for biotech, says Morningstar's Lauren Migliore.
The battle over Cole III has taken a new twist, as shareholders sued to block the REIT's internal merger. Meanwhile, suitor American Realty Capital waits in the wings.
The firm's many mergers have yielded some good funds, though beware the price tags.
These management teams should be good stewards of shareholder capital in today's uncertain environment.
©2012 Morningstar Advisor. All right reserved.